阿尔尼拉姆制药

Alnylam Pharmaceuticals: Bollinger Bands Expand Upward, KDJ Golden Cross Indicating Bullish Trend

Alnylam Pharmaceuticals' 15min chart shows Bollinger Bands Narrowing, KDJ Death Cross triggered.

Alnylam Pharmaceuticals: RSI Oversold, KDJ Golden Cross Triggers 15min Chart Analysis

Roku

Alnylam Pharmaceuticals

Alerus Financial

Peraso

Wix.com

10 Undervalued Stocks with Estimated Discounts of Up to 49.2%

Catalyst<ul> <li>Most analysts rate ALNY Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Bearish signals are obviously dominant (4 bearish vs 1 bullish) according to recent technical indicators.</li> <li>Recent technical signals are scarce, and the market is relatively calm, indicating unclear directionality.</li></ul>

Key Factors

Alnylam Pharmaceuticals (ALNY) closed with a 0.93% decline on February 6, 2026, as trading volume plummeted 44.26% to $490 million, ranking 308th in market activity. Executive vice presidents at Alnylam sold shares totaling $1.55 million in January, and analysts at Bank of America and HC Wainwright reduced price targets to $462 and $510 respectively. Alnylam Pharmaceuticals is trading at a 49.2% discount to its estimated fair value, according to an article highlighting undervalued stocks based on cash flow analysis. Alnylam’s shares fell 12% over 30 days as of February 4, 2026, despite delivering a 29.8% total shareholder return over the past year.

Recent Updates

ALNY News